Overall verdict
Buy
6.9/10
1-year performance
-27.42%
Score breakdown
Down 27.4% over 1 year, 6% of the 52-week range.
Strongest: Profitability 9.2/10. Weakest: Shareholder return 6.0/10.
28 analysts, target +0.3% vs the price.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism ;
traditional brain and open skull based surgical procedures products ; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications.
The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
United States
CEO
Kevin Lobo
Founded
1941
Employees
56 000
Revenue / employee
448 500 USD
Next earnings
October 30, 2026 (estimated)
Institutional holders
- BlackRock, Inc.7.16%
- VANGUARD CAPITAL MANAGEMENT LLC5.89%
- JPMORGAN CHASE & CO4.51%
- STATE STREET CORP4.06%
- GREENLEAF TRUST3.98%
- PRICE T ROWE ASSOCIATES INC /MD/3.11%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.14%
- WELLINGTON MANAGEMENT GROUP LLP2.13%
- GEODE CAPITAL MANAGEMENT, LLC2.04%
- Other institutions45.34%
- Rest of the register19.63%
2257 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
392.55 USD
52-week low
267.00 USD
1-year performance
-27.42%
Declining
Year-to-date performance
-22.17%
Declining
Drawdown
-30.18%
Major drawdown
Position in the 52-week range
6% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 1.7 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Stryker | 110 621 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 1.7 times as much as the world ETF.
- Worst fall:-44 % between February 2020 and March 2020. 10,000 € placed at the top fell to 5 637 €. The world ETF, at worst: -34 %. Back to its high in 12 months.
Stryker earned more than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Stryker: 110 621 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 240.80 USD - 268.31 USD (comparables only)
The price implies growth of 6.42% per year; the company grows at 14.84%.
Gross margin 63.0%, net margin 14.4%, ROIC 10.0%, ROE 16.5%.
Net margin
14.43%
Exceptional
Sector 8.18%|S&P 12.97%
Gross margin
62.97%
Fair
Return on equity (ROE)
16.51%
Exceptional
Sector 6.97%|S&P 16.52%
Return on invested capital (ROIC)
9.95%
Exceptional
Free cash flow margin (FCF)
18.20%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.26x
High
Margin stability
4.5 pts
Steady
Revenue to net income
Growth
8.2/10Revenue up 9.4% over 1 year, 11.8% a year over 5, EPS 14.8% a year over 5.
Revenue (trailing 12 months)
25.8Md USD
Revenue growth (1y)
9.42%
Solid
Revenue growth (3y)
36.14%
Solid
EPS growth (1y)
44.49%
Hyper-growth
EPS CAGR (5y)
14.84%
Exceptional
EPS revisions (3 months)
0.05%
Revised up
Valuation
6.1/10P/E 28.4x, forward P/E 21.3x, EV/EBITDA 16.3x, PEG 1.91. The multiple sits in the 2th percentile of its own 5-year history.
P/E (TTM)
28.4x
Fair
Sector 29.3x|S&P 23.0x
Forward P/E
21.3x
Fair
EV / EBITDA
16.3x
Fair
Sector 16.0x|S&P 14.5x
PEG
1.91
Expensive
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
254.56 USD
Fairly priced
P/E vs its own 5-year history
among the 2% lowest valuations
Far cheaper than usual
Market cap
105Md USD
Financial strength
7.1/10Cash covers 22.5% of the debt, net debt/EBITDA 1.7x.
Net debt / EBITDA
1.7x
Tight
Gearing (net debt / equity)
49.90%
Solid
Cash
3.5Md USD
Cash / market cap
3.31%
Tight
Cash / total debt
22.50%
Tight
Interest coverage
9.8x
Solid
Net debt
12.0Md USD
Equity
24.0Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 269.75 USD
- MM20290.53
- MM50316.47
- MM200332.54
- RSI 1429.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-2.24%
200-day average slope, 3 months
-4.73%
50-day average slope, 1 month
-3.34%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.34 % per day
Volatility change
+11.13%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 12.86 (10) | 14.99 (27) | 27 235 (27) | 7 799 (15) | 4 939 (7) |
| 2027 | 14.72 (10) | 16.72 (27) | 29 602 (27) | 8 568 (15) | 5 740 (7) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 25, 2026.
Same sub-industry: 190 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BSX | 7.0 | 7.2 | 64.7Md USD | 18.1x | 17.5 % | 7.5 % | 10.5 % | 1.8x | 5.6 % | -54.3 % | ||
| 2 | MDT | 7.0 | 7.1 | 114Md USD | 22.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 5.4 % | -6.7 % | ||
| 3 | SYK | 6.9 | 7.4 | 105Md USD | 28.4x | 14.4 % | 9.4 % | 10.0 % | 1.7x | 4.5 % | -27.4 % | ||
| 4 | ABT | 6.6 | 6.3 | 179Md USD | 33.5x | 11.6 % | 13.0 % | 7.5 % | 0.5x | 4.4 % | -25.3 % | ||
| 5 | ISRG | 6.5 | 6.8 | 141Md USD | 45.6x | 28.4 % | 18.5 % | 17.4 % | -1.6x | 2.3 % | -11.4 % | ||
| 6 | IDXX | 6.3 | 6.4 | 41.1Md USD | 36.7x | 25.0 % | 9.7 % | 56.6 % | 0.5x | 3.0 % | -20.4 % | ||
| 7 | SHL | 6.3 | 6.5 | 47.2Md USD | 18.9x | 9.6 % | 1.8 % | 7.4 % | 2.7x | 5.4 % | -20.5 % | ||
| 8 | EW | 6.2 | 5.6 | 50.0Md USD | 51.5x | 15.0 % | 13.6 % | 8.7 % | -2.0x | 2.9 % | 15.4 % | ||
| 9 | BDX | 5.7 | 5.1 | 49.7Md USD | 55.1x | 6.2 % | 5.4 % | 3.2 % | 3.4x | 5.1 % | 22.7 % |
